Clinical Trials Browser

Phase 1 × imgatuzumab × Tumor-Agnostic × Clear all

NCT00721266 2016-11-02

A Dose-Escalation Study of RO5083945 in Patients With Metastatic and/or Locally Advanced Malignant Epidermal Growth Factor Receptor (EGFR)+ Solid Tumors.

Phase 1 Completed

Neoplasms